Results 51 to 60 of about 16,074 (250)
Pharmaceuticals, 2021 Headaches are frequently described in progressive multiple sclerosis (PMS) patients, but their mechanism remains unknown. Transient receptor potential ankyrin 1 (TRPA1) was involved in neuropathic nociception in a model of PMS induced by experimental ...
Diéssica Padilha Dalenogare +15 more
doaj +1 more source
DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. [PDF]
, 2019 BackgroundThe commercial formulation of sumatriptan nasal spray is an effective option for migraine patients requiring or preferring a non-oral route of drug administration, but its utility is limited by poor absorption and tolerability issues. DFN-02, a
Brand-Schieber, Elimor +3 more
core
Headache: The Journal of Head and Face Pain, EarlyView.Sleep restriction (SR) and caffeine intake act as environmental modulators of migraine susceptibility. Their effects are sex‐dependent: Females show heightened sensitivity under both SR and caffeine conditions. Males require the combination of SR and caffeine to exhibit susceptibility.
Gabriel Camargo de Oliveira +7 more
wiley +1 more source
Неврология, нейропсихиатрия, психосоматика, 2018 Migraine is a chronic brain disease with a high prevalence and a marked deterioration in quality of life. Triptans are the gold standard for migraine attack therapy, but they are not effective in all patients.
K. V. Skorobogatykh, Yu. E. Azimova
doaj +1 more source
Subtype-Specific Off-Label Treatment of Rosacea
Case Reports in Dermatology, 2021 We present 2 cases of rosacea that were successfully managed with off-label treatment. The first is a case of painful, exuding papulopustular lesions of the nose treated with rifaximin, and the other is a case of severe, debilitating and painful flushing
Nita Wienholtz +3 more
doaj +1 more source
Network meta-analysis of migraine disorder treatment by NSAIDs and triptans [PDF]
, 2016 Node splitting of direct and indirect comparisons according to type of interventions for rescue medication and recurrence.
Haiyang Xu +3 more
core +2 more sources
Journal of the Royal Society of New Zealand, Volume 56, Issue 3, June 2026.Cost of illness (COI) studies are used to quantify the economic burden of disease on health systems, employers and society, and identify where costs may be saved by improvements in disease management. Many migraine COI studies have been published internationally but none have included data from Aotearoa New Zealand (NZ), despite the known high ...
Fiona Imlach +5 more
wiley +1 more source
Sensors, 2023 Sumatriptan is an organic chemical compound from the tryptamine group. It is used as a medicine for migraine attacks and in the treatment of cluster headaches.
Joanna Smajdor +3 more
doaj +1 more source
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. [PDF]
, 2018 BackgroundIn a previous randomized, double-blind, proof-of-concept study in rapidly escalating migraine, a 3 mg dose of subcutaneous sumatriptan (DFN-11) was associated with fewer and shorter triptan sensations than a 6 mg dose.
Brand-Schieber, Elimor +3 more
core +1 more source
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine [PDF]
, 2004 Background: Calcitonin gene–related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks.
Diener, H.-C. +7 more
core +1 more source